Medical Condition News

RSS

Alimera reports 36-month results from ILUVIEN Phase 3 FAME study for DME

Alimera Sciences, Inc., a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today reported results through month 36 of the completed FAME™ Study.

4 Feb 2011

Positive top-line results from ILUVIEN Phase 3 trial in patients with DME

pSivida Corp., a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, including the investigational drug ILUVIEN for the treatment of Diabetic Macular Edema, today announced month 36, top-line readout results for the FAME Study prepared by its licensee, Alimera Sciences.

4 Feb 2011

ConforMIS receives FDA 510(k) clearance for iTotal CR Knee Replacement System

ConforMIS has received 510(k) clearance from the U.S. Food and Drug Administration to commercially market its iTotal® CR Knee Replacement System. The iTotal CR is the only true patient-specific system available for patients who would traditionally receive a standard total knee replacement (TKR).

4 Feb 2011

Study: Pistachios may help reduce risk of heart disease

It's no coincidence that National Pistachio Day – February 26, 2011 – occurs during American Heart Month. Heart disease remains the leading cause of death in America, and promising nutrition research shows that pistachios are a heart healthy snack choice. In honor of American Heart Month, TheGreenNut.org is offering simple tips encouraging all Americans to go green for a healthy heart this February.

4 Feb 2011

Immune protein exacerbates skin cancer due to sun exposure: Study

An unexpected immune protein exacerbates cancer due to sun exposure, report researchers in the January 27th issue of Nature. The study suggests that drugs blocking the protein might halt tumor growth in skin cancer patients.

3 Feb 2011

FDA approves Hospira's topotecan for SCLC

Hospira, Inc., the world leader in generic injectable pharmaceuticals, today announced U.S. Food and Drug Administration (FDA) approval of Topotecan Injection, the first solution formulation of the oncology drug approved in the United States.

3 Feb 2011

Ceregene initiates enrollment and dosing in CERE-120 Phase 2b trial for Parkinson's disease

Ceregene, a biopharmaceutical company, announced today that it is progressing with enrollment and dosing in its CERE-120 Phase 2b multi-center, sham-surgery, double-blinded controlled trial in Parkinson's disease.

3 Feb 2011

Philanthropist awards Mayo Clinic $100 million to establish Proton Beam Therapy Program

Mayo Clinic today announced long-time patient and philanthropist Richard O. Jacobson has given a $100 million gift to help establish the multi-site Mayo Clinic Proton Beam Therapy Program. This is the largest outright gift in the clinic's history, as well as the largest gift Mr. Jacobson has made to any single institution.

3 Feb 2011

Genetic component to Parkinson’s disease discovered

Parkinson’s disease, a severely degenerative disease of the brain leading to tremors, muscle rigidity and finally immobility was until the 1990’s believed to be due to environmental factors, lifestyle and a person’s age. However, now scientists have discovered five more genes that influence its development.

3 Feb 2011

Rare new disease identified – calcium accumulates in blood vessels

A new rare disease has been identified. Louise Benge’s started having difficulty in walking when she was 25. She developed hardening and pain over her calves and hands. She worsened over the next 20 years. Her family physician in Mount Vernon, Ky., was at a loss, as were a vascular specialist, a hand specialist and a kidney specialist. Her two sisters and two brothers had the problem too, but no doctor could understand why.

3 Feb 2011

Longer life with osteoporosis therapy: Study

In a new breakthrough, Australian scientists have identified the “remarkable” life-extending properties of an osteoporosis treatment. The research is published in the Journal of Endocrinology and Metabolism on Thursday.

3 Feb 2011

Cancer Research UK launches 'Musicommercial' to help beat cancer

The first ever 'Musicommercial' is unveiled today to launch this year's Tesco and Cancer Research UK's Race for Life - the UK's largest women-only fundraising event series.

3 Feb 2011

Positive results from Derma Sciences' Phase 2 trial with DSC127 in patients with diabetic foot ulcers

Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today announced positive results from its Phase 2 clinical trial with DSC127 in patients with diabetic foot ulcers, including meeting the trial's primary endpoint, the proportion of study ulcers healed by 12 weeks as defined by 100% epithelialized with no drainage, as well as all secondary endpoints measured at this time.

3 Feb 2011

Innovative Heart Attack Rapid Response Team for snow shoveling heart attacks

Loyola's innovative Heart Attack Rapid Response Team (HARRT) is on staff 24/7 to perform emergency surgery on patients who have experienced heart attacks from shoveling snow or other causes.

3 Feb 2011

Surrogate questions imaging can answer about cancer

A Professor who is investigating how modern body imaging techniques can be adapted to answer new questions - such as the anti-cancer properties of fish oils and green tea, or establishing cause of death in forensic investigation - is to give a free public lecture at the University of Leicester.

3 Feb 2011

AVEO receives USAN, WHO generic name approval for ficlatuzumab

AVEO Pharmaceuticals, Inc. today announced that the United States Adopted Names (USAN) Council, in consultation with the World Health Organization (WHO) International Nonproprietary Names Expert Committee, has approved the use of the nonproprietary generic name "ficlatuzumab" (pronounced fye" kla tue' zue mab) for AV-299, a potent, functional anti-HGF/c-MET antibody internally discovered at AVEO.

3 Feb 2011

Consumer Reports Health unveils ratings of nine common screenings for heart disease

Consumer Reports Health unveils Ratings of nine common screenings for heart disease based on systematic review of evidence; some screenings work well while others deemed not worth the risk for healthy individuals

3 Feb 2011

USF Health sponsors conference on Parkinson's disease and multiple sclerosis

Some of the country's leading physicians and researchers in the fields of Parkinson's disease and multiple sclerosis will gather later this month to discuss the latest advances in the diagnosis and treatment of these neurological disorders.

3 Feb 2011

Chances of surviving cardiac arrests high in large public venues having AEDs

A study of more than 14,000 men and women whose hearts stopped suddenly suggests that the chances of survival are very high if such cardiac arrests are witnessed in large public venues, including airports, sports arenas or malls. The reasons, researchers say, are that almost four out of five such cases appear to be due to a survivable type of heart rhythm disruption and that big places with lots of people are more likely to have an automated external defibrillator, or AED device, handy, along with those who can apply it as well as CPR.

3 Feb 2011

PanCare Childhood and Adolescent Cancer Survivor Care and Follow-up Studies to kick off in Lund, Sweden

By learning more about these late effects of treatment, the health care services can, on the one hand, improve and reduce the intensity of the treatment, and, on the other hand, find appropriate ways to care for those suffering from side-effects of the treatment in adolescence and adulthood.

3 Feb 2011